Determination Of The Ability Of A Novel, Long-Acting PLGA Subcutaneous GnRH Antagonist To Castrate Without A Testosterone Surge In A Rat Model

Advanced prostate cancer treatment often relies on androgen deprivation therapy. While traditional options frequently trigger an initial testosterone surge, alternative approaches utilizing gonadotropin-releasing hormone antagonists can achieve castrate levels rapidly without causing this initial flare.

Recent evaluations in rodent models demonstrate that novel, low-volume polymeric subcutaneous depot formulations can successfully suppress testosterone to undetectable levels within twenty-four hours. A single administration maintains sustained therapeutic drug exposure and reliable suppression for over six months without requiring high-volume loading doses. These findings highlight a promising pathway toward improving patient convenience and therapeutic outcomes in long-term oncological care.

Explore the complete scientific poster to review the comprehensive pharmacokinetic data and formulation details.